(Q46597433)

23 December 2017

title

Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials (English)

1 reference

23 December 2017

main subject

phase II clinical trial

0 references

phase I clinical trial

0 references

1 reference

Stefaan van Gool

1

1 reference

23 December 2017

publication date

1 October 2013

1 reference

23 December 2017

published in

Immunotherapy

1 reference

23 December 2017

volume

5

1 reference

23 December 2017

issue

10

1 reference

23 December 2017

page(s)

1043-1046

1 reference

23 December 2017

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

cites work

1 reference

Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report

21 January 2018

1 reference

Dendritic cell therapy of high-grade gliomas.

21 January 2018

1 reference

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

21 January 2018

1 reference

Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination

21 January 2018

1 reference

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

21 January 2018

1 reference

Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate.

21 January 2018

1 reference

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

21 January 2018

1 reference

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

21 January 2018

1 reference

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.

21 January 2018

1 reference

Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.

21 January 2018

1 reference

Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma.

21 January 2018

1 reference

Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele.

21 January 2018

1 reference

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.

21 January 2018

1 reference

Resection and Immunotherapy for Recurrent Grade III Glioma

21 January 2018

1 reference

Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.13.86

1 reference

23 December 2017

1 reference

23 December 2017